New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
07:36 EDTCYTKCytokinetics presents analyses from Tirasemtiv clinical trials in ALS patients
Cytokinetics announced a platform presentation of pharmacokinetic data and pharmacokinetic/pharmacodynamic analyses from three previously-reported clinical trials of tirasemtiv in patients with amyotrophic lateral sclerosis, or ALS, at the 23rd International Symposium on ALS and Motor Neurone Diseases, or ALS/MND, in Chicago, IL. Tirasemtiv selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, which increases skeletal muscle force in response to neuronal input. In preclinical studies, this mechanism has been shown to delay the onset and reduce the degree of muscle fatigue. Tirasemtiv is currently being evaluated in BENEFIT-ALS, an international, double-blind, randomized, placebo- controlled, Phase IIb clinical trial designed to evaluate the safety, tolerability and potential efficacy of this novel drug candidate in patients with ALS.
News For CYTK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
16:19 EDTCYTKCytokinetics sees initiating phase 3 tirasemtiv program in Q2
Cytokinetics (CYTK) expects to initiate a phase III clinical development program for tirasemtiv in patients with ALS in Q2. Cytokinetics expects to initiate a phase II trial of CK-2127107 in patients with SMA in 2H. Cytokinetics expects results from COSMIC-HF to be available in 2H. Cytokinetics expects to continue joint development activities in collaboration with Amgen (AMGN) directed to the potential advancement of omecamtiv mecarbil to phase III clinical development.
16:17 EDTCYTKCytokinetics reports Q1 EPS (23c), may not compare to consensus (12c)
Reports Q1 revenue $4.41M, may not compare to consensus $10.08M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use